Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease characterized by the loss of tolerance to nuclear antigens, immune complex formation and inflammation in multiple organs. The disease is very heterogeneous, and most clinicians consider SLE as a group of diseases with similar features where the pathogenesis is driven by a combination of genetic and environmental factors. One of the most prominent features, shared by the majority of patients with SLE, is a continuous activation of the type I interferon (IFN) system, which manifests as increased serum levels of IFNα and/or an increased expression of type I IFN-induced genes, a so-called type I IFN signature. The mechanisms behind this IFN signature have partly been clarified during recent years, although the exact function of the IFN-regulated genes in the disease process is unclear. In this review, we will describe the type I IFN system and its regulation and summarize the numerous findings implicating an important ethiopathogenic role of a dysregulated type I IFN system in SLE. Furthermore, strategies to therapeutically target the type I IFN system that are currently evaluated preclinically and in clinical trials will be mentioned.

Radon activity concentration--a Euromet and BIPM supplementary comparison.

For the first time, a comparison of radon activity concentration in air has been performed within the scope of Euromet. In the project 657, 'Comparison of calibration facilities for the radon activity concentration,' 12 participants from 9 countries compared different radon reference atmospheres at 1, 3 and 10 k Bq m-3 via a transfer standard. The comparison was listed as BIPM supplementary comparison EUROMET.RI(II)-S1. The results of most participants are correlated due to common traceability to one single radon gas standard producer. This makes a careful correlation analysis necessary to achieve an appropriate comparison reference value. The results of the comparison as well as the complex analysis of the correlated set of data is presented and discussed.

Reorganization of craniofacial/cleft care delivery: the Massachusetts experience.

Until 1989, the Commonwealth of Massachusetts operated a mandated care program known as Services for Handicapped Children (SHC) for children with cleft lip/palate or craniofacial anomalies. During the mid 1980s, the federal government reduced its block grant funds and encouraged the Commonwealth of Massachusetts to develop Project SERVE to address this changing fiscal reality. The principal outcome of Project SERVE was the recommendation that the SHC direct care programs, including all craniofacial and cleft palate clinics, should be dismantled over a number of years. However, due to the economic recession, all government funding was suddenly withdrawn from cleft palate teams and the state-run SHC clinics were abruptly dissolved. To treat patients left without coordinated care, former team members reassembled and began a new craniofacial team based at the University of Massachusetts Medical Center. Difficulties with the transition of the clinic included recruiting and retaining team members; remuneration procedures for team members; maintenance of patient records previously kept by the state; coordination of clinical/clerical responsibilities; identifying a physical locale to hold the clinics; and solicitation of referring health care provider referrals and follow-up. All these issues required specific interventions that are presented in this paper. Project SERVE, begun under federal auspices, in the Commonwealth of Massachusetts, has recently been promoted as a model for a new and improved approach to the management of cleft palate and craniofacial care delivery nationwide. Awareness of the potential for abrupt, radical change in funding for federally mandated cleft/craniofacial care is essential, and a successful transition to a medical center-based model is possible using the procedures established at our center.

Some tests on measuring methods for indoor radon using activated charcoal.

Two methods for measuring indoor radon concentrations using activated charcoal have been tested. The first method is the well-known technique with direct gamma-measurements on the exposed canister after the sampling period. The other method uses a thermoluminescence dosemeter placed in the charcoal canister, giving an integrated value of the radon concentration.